Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson reports healthcare developments across its Innovative Medicine and MedTech businesses. News commonly covers clinical and scientific data in immunology, oncology, neurology and neuropsychiatry, including medicines and candidates such as CAPLYTA, TREMFYA, JNJ-4804, seltorexant and the INVEGA long-acting injectable schizophrenia portfolio.
Company updates also include medical technology programs such as the investigational OTTAVA robotic surgical system, product and patient-education initiatives, quarterly sales and earnings releases, dividend actions, investor presentations and governance or investor-relations appointments.
Johnson & Johnson (NYSE: JNJ) will host an investor conference call at 8:30 a.m. ET on Tuesday, October 13 to review third-quarter results. CEO Joaquin Duato, CFO Joseph J. Wolk and VP Investor Relations Ryan Koors will lead the call, with other executives joining the Q&A portion. The webcast, presentation materials and the related press release (available around 6:45 a.m. ET that morning) can be accessed via www.investor.jnj.com.
Johnson & Johnson (NYSE: JNJ) announced that the U.S. FDA has approved IMAAVY (nipocalimab-aahu) as the first treatment specifically for warm autoimmune hemolytic anemia (wAIHA) in adults and pediatric patients ≥12 years currently or previously treated with corticosteroids, following Priority Review.
The approval is based on the Phase 2/3 randomized, placebo-controlled ENERGY trial, where approximately three times as many patients on the approved 30 mg/kg IV every 4 weeks dose achieved durable hemoglobin response versus placebo by Week 24. IMAAVY-treated patients showed a mean hemoglobin increase of 1 g/dL at Week 1 and a 3.5‑point higher mean FACIT‑Fatigue score at Week 24 versus placebo. The safety profile was consistent with prior experience in generalized myasthenia gravis; common adverse reactions in wAIHA included peripheral edema, diarrhea, and fever.
Johnson & Johnson (NYSE: JNJ) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026. Company management is scheduled for a Fireside Chat at 11:30 a.m. Eastern Time, accessible via live audio webcast on Johnson & Johnson's investor relations website, with a replay available afterward.
Johnson & Johnson (NYSE: JNJ) will present at the 2026 Wells Fargo Healthcare Conference on Wednesday, September 9, 2026. Company management will join a Fireside Chat at 11:00 a.m. Eastern Time, with a live audio webcast and archived replay accessible via Johnson & Johnson’s investor relations website.
Johnson & Johnson (NYSE: JNJ) announced that Jennifer Taubert will retire as Executive Vice President, Worldwide Chairman, Innovative Medicine after more than 21 years at the company. Under her leadership, the Innovative Medicine business grew to over $60 billion in annual revenue.
Tom Cavanaugh, currently Company Group Chairman, North America, Innovative Medicine, will succeed her as EVP, Worldwide Chairman, Innovative Medicine and join the Executive Committee effective September 1, 2026. Johnson & Johnson highlighted his nearly 30 years of biopharmaceutical experience and prior leadership roles in oncology, immunology and global commercial strategy.
Johnson & Johnson (NYSE: JNJ) announced that the U.S. FDA has granted Priority Review to a supplemental Biologics License Application for subcutaneous RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as a potential treatment for adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease has progressed after platinum-based chemotherapy and PD‑1/PD‑L1 therapy.
The Priority Review, which shortens review to about six months, is supported by pivotal Phase 1b/2 OrigAMI‑4 data showing a 42% overall response rate with monotherapy subcutaneous amivantamab, with more than one‑third of responders achieving complete responses. RYBREVANT FASPRO is already approved in over 40 countries as a subcutaneous therapy for EGFR‑mutated non‑small cell lung cancer and is the only therapy in head and neck cancer engineered to target both EGFR and MET.
Johnson & Johnson (NYSE: JNJ) has completed its acquisition of Firefly Bio, a biotechnology company developing the proprietary Firelink™ degrader antibody conjugate (DAC) platform, for $1 billion in cash. The deal broadens Johnson & Johnson’s oncology portfolio and is intended to advance targeted therapies for difficult-to-treat solid tumors, including KRAS-driven cancers.
According to the company, the Firelink™ DAC platform is designed to deliver highly selective protein degraders directly to cancer cells, aiming to maximize tumor targeting while preserving healthy tissue. The transaction will be accounted for as an asset acquisition, creating an approximately $1 billion in-process R&D charge in Q3 2026 and is expected to dilute adjusted EPS by about $0.46 in 2026 and $0.08 in 2027.
Johnson & Johnson (NYSE: JNJ) announced strategic agreements with Sail Biomedicines to advance in vivo CAR-T programs for immune‑mediated diseases and expand Sail’s platform to additional targets. The collaboration agreement is with Janssen Biotech, a Johnson & Johnson company, and the equity investment is made by Johnson & Johnson Innovation – JJDC.
According to Johnson & Johnson, total initial payments are expected to be $785 million, including a $465 million equity investment and up to $140 million in contingent development milestone payments. Johnson & Johnson also receives an exclusive option to acquire Sail for $2.58 billion. If the option is exercised, the company expects dilution of approximately $0.18 to adjusted operational EPS and adjusted EPS in 2026 and approximately $1.28 in 2027. The transactions are subject to regulatory approvals and other conditions.
Covista (NYSE: CVSA) appointed Emily C. Chiu and Leslie Storms to its Board of Directors, effective August 17, 2026, as the company advances its three-year “Purpose at Scale” growth strategy to address U.S. healthcare workforce shortages.
Chiu brings CEO-level experience in technology, fintech and edtech, including leadership roles at Novo Platform and Block’s open-source platform and Cash App. Storms is Chief Operating Officer of National Veterinary Associates and previously held senior MedTech leadership roles at Johnson & Johnson. With these appointments, 10 of Covista’s 12 directors are independent, supporting governance as the company focuses on operational excellence, expansion into adjacent healthcare domains, direct workforce pipelines with employer partners and AI-enabled healthcare education innovation.
Johnson & Johnson (NYSE: JNJ) announced an agreement in principle to comprehensively resolve its remaining ovarian talc litigation with plaintiff firms leading the federal MDL and related state cases. The proposed resolution is conditioned on participation covering at least 95% of the remaining roughly 76,000 claims.
The structure calls for per-claim payments within a $5.5 billion total commitment, with a first payment of no more than $3 billion in 2027 and no further payments before 2028. According to the company, this follows a favorable MDL specific-causation ruling and complements prior settlements of about 95% of mesothelioma suits, all state consumer protection actions, and all talc-supplier disputes.